Healthcare
Lantheus Holdings, Inc.(LNTH)
Live Price
Offline$104.52
+0.19% today
1Y Change
+29.94%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $5.57B
- Revenue Growth
- +0.5%
- EPS Growth
- -23.5%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lantheus Holdings, Inc. (LNTH) is a Healthcare stock with a market cap of $5.57B and listed on NASDAQ. The stock last traded around $104.52 and up 29.9% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +0.5%, EPS growth of -23.5%, a dividend yield of 0.0%. What stands out right now is revenue +0.5%, EPS -23.5%, free cash flow -28.2% with operating margin 20.2% and ROIC 12.2%. Valuation is more restrained than many high-expectation growth names at P/E 24.0 and price/sales 3.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LNTH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.5% vs +7.6% peer median
Operating Margin
Near sector median
+20.2% vs +19.4% peer median
P/E
Below sector median
24.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +0.5% and EPS is at -23.5%, with operating margin around 20.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +5.6% | +12.0% | +19.3% |
2026 Feb 26, 2026 | +41.5% | -0.7% | +1.2% | +1.2% |
2025 Nov 6, 2025 | +0.0% | -4.9% | -1.1% | +17.9% |
Benchmark Edge
LNTH vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LNTH
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LNTH Max Drawdown
-40.22%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LNTH and SPY.
Company Overview
Lantheus Holdings, Inc.
NASDAQ Global Market
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
- Leadership
- Mary Anne Heino
- IPO Date
- Jun 25, 2015
- Employees
- 808
- Street Address
- 331 Treble Cove Road
- Mailing
- Bedford, MA, 01862
- Region
- Bedford, MA, US
- Reporting Currency
- USD
- Investor Line
- 978 671 8001
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 24.0
- EV/EBITDA
- 14.6
- Price/Sales
- 3.6
- Price/Book
- 5.2
Growth
- Revenue
- +0.5%
- EPS
- -23.5%
- Free Cash Flow
- -28.2%
Profitability
- Gross Margin
- 61.1%
- Operating Margin
- 20.2%
- Net Margin
- 15.2%
- ROE
- 20.6%
- ROIC
- 12.2%
Balance Sheet
- Debt/Equity
- 0.62
- Current Ratio
- 2.70
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.